Atul Pande - Mar 18, 2024 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role
Director
Signature
/s/ Jason Brown, Attorney-in-Fact
Stock symbol
KRTX
Transactions as of
Mar 18, 2024
Transactions value $
-$6,259,679
Form type
4
Date filed
3/18/2024, 04:30 PM
Previous filing
Dec 5, 2023
Next filing
Apr 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Disposed to Issuer -$327K -990 -100% $330.00 0 Mar 18, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Disposed to Issuer -$2.91M -12.5K -100% $232.41 0 Mar 18, 2024 Common Stock 12.5K $97.59 Direct F1, F3, F4
transaction KRTX Option (right to buy) Disposed to Issuer -$1.72M -8.5K -100% $201.99 0 Mar 18, 2024 Common Stock 8.5K $128.01 Direct F1, F3, F4
transaction KRTX Option (right to buy) Disposed to Issuer -$1.14M -5K -100% $227.04 0 Mar 18, 2024 Common Stock 5K $102.96 Direct F1, F3, F4
transaction KRTX Option (right to buy) Disposed to Issuer -$176K -1.9K -100% $92.30 0 Mar 18, 2024 Common Stock 1.9K $237.70 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Atul Pande is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
F2 Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.
F3 Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.
F4 These Options are fully vested.
F5 These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date.